Clinical and bioanalytical contract services provider SGS has announced the forthcoming availability of a new strain of influenza virus for use as a challenge agent in clinical trials. The synthetic virus may be used to test the efficacy of both novel influenza drugs and vaccines in healthy volunteers. The new agent is a H3N2 type virus, which represents one of the common current circulating strains of influenza of a pandemic origin. Its manufacture has been undertaken by SGS in accordance wi...